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Abstract
Background: Eradication of early gastric carcinoma (GC) is thought to contribute to reduction in the mortality of GC, 
given that most of the early GCs progress to the advanced GCs. However, early GC is alternatively considered a 
dormant variant of GC, and it infrequently progresses to advanced GC. The aim of this study was to clarify the extent of 
overlap of genetic lineages between early and advanced tubular adenocarcinomas (TUBs) of the stomach.
Methods: Immunohistochemical staining for p53 was performed using 28 surgically resected stomachs with 13 
intramucosal and 15 invasive TUBs. By chromosome- and array-based comparative genomic hybridization (CGH), 
genomic copy number constitution was compared between the mucosal and invasive parts of the invasive TUBs and 
between the mucosal parts of the invasive and intramucosal TUBs, using 25 and 22 TUBs, respectively. TP53 mutation in 
exons 5-8 was examined in 20 TUBs.
Results: Chromosomal CGH revealed that 4q+ and 11q+ were more common in advanced and early TUBs, 
respectively, whereas copy number changes in 8q and 17p showed no significant differences between early and 
advanced TUBs. However, array CGH revealed that, of the 13 intramucosal TUBs examined, loss of MYC (MYC-) and gain 
of TP53 (TP53+) was detected in 9 TUBs and MYC+ and/or TP53- was detected in 3 TUBs. Of the mucosal samples of 9 
invasive TUBs, 7 showed MYC-/TP53+ and none showed MYC+ and/or TP53-. Of the 9 samples from the invasive parts, 1 
(from submucosal cancers) showed MYC-/TP53+ and 6 (1 from submucosal and 5 from advanced cancers) showed 
MYC+ and/or TP53-. The latter 6 tumours commonly showed a mutant pattern (diffuse or null) in p53 
immunohistochemistry, and 4 of the 6 tumours assessable for TP53 sequence analysis revealed mutations. The overall 
array CGH pattern indicated that, between the mucosal and invasive parts, genetic lineage was found discontinuous in 
5 advanced cancers and continuous in 3 submucosal cancers.
Conclusions: Genetic lineages often differed between early and advanced TUBs. MYC-/TP53+ and MYC + and/or TP53- 
may be the signatures of dormant and aggressive TUBs, respectively, in the stomach.
Background
Gastric cancer remains the second most common cause
of cancer-related deaths worldwide, despite a recent
decrease in its mortality in developed countries [1]. Gas-
tric carcinomas (GCs) are classified morphologically into
2 major categories: tubular-forming type and diffuse type
[2,3] and, in staging, into early cancers (involving the
mucosa and the submucosa) and advanced cancers
(involving the muscularis propria or deeper). Early GC is
considered a curable cancer [4]; it reportedly progresses
to advanced GC after varying durations as an early stage
of GC [5,6]. In Japan, early GCs can be actively resected
endoscopically as well as surgically [7], based on the prin-
ciples of early detection and treatment. On the other
hand, some pathologists maintain that the tubular-form-
ing neoplastic lesions that are confined to the mucosa
take a long time to or are unable to invade deeper tissues.
Thereby, these lesions are called dysplasia [4].
Recently, a mass-screening program for neuroblasto-
mas in Japan [8-10] was suspended because a discontinu-
ous genetic lineage was found between the early- and the
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late-presenting neuroblastomas. Negative and late-pre-
senting (≥1 year) neuroblastomas showed near-diploidy
with loss of terminal 1p, whereas positive neuroblasto-
mas in infants showed near-triploidy without 1p deletion
[11,12]. On the other hand, comparative genomic hybrid-
ization (CGH)-based analysis suggested that high-grade
atypical adenomatous hyperplasia in the lung is the true
precursor of bronchioloalveolar carcinoma [13]. In the
stomach, it is a problem to what extent genetic lineage is
overlapped in early and advanced GCs.
In diffuse type GCs, we used CGH to demonstrate that
chromosomal copy-number alterations in the intramu-
cosal signet-ring cell carcinomas that showed a layered
structure [14] were inherited in a fraction of poorly dif-
ferentiated GCs at advanced stages [15]. The presence of
a layered structure of signet ring cells in the mucosal
parts of these advanced cancers also suggested that signet
ring cell carcinomas may be a true precursor of poorly
differentiated GCs. CGH-based lineage analysis of
another subset of poorly differentiated advanced GCs
with tubular components but no layered structure in the
mucosal part revealed that GCs of this subset were
derived from a tubular component in a tumour and were
characterized by 17p- and 8q+ [16] and inactivation of
the wild-type TP53 by mutation and loss of heterozygos-
ity (LOH) [17]. In order to determine the early-stage
counterpart of this type of GC, we analysed intramucosal
tubular adenocarcinomas (TUBs) using CGH. These
studies found that the intramucosal TUBs showed not
only several chromosomal changes common to advanced
GCs but also frequently showed 8q- and 17p + that were
critically different from advanced and poorly differenti-
ated GCs [18].
In the present study, copy-number changes of chromo-
somes and genes were examined in the mucosal and inva-
sive parts of another series of early and advanced TUBs
using array and chromosomal CGH. Based on these data,
we demonstrated cases of continuous and discontinuous
lineages between intramucosal and invasive parts of indi-
vidual tumours and found that TP53 and MYC may be
good lineage markers for gastric TUBs.
Methods
The Institutional Review Board on Medical Ethics at
Shiga University of Medical Science granted approval for
conducting this research on the condition that the mate-
rials used must be anonymous.
Tumour samples
This study included 28 surgically resected stomachs
(Table 1) with 13 intramucosal TUBs and 15 invasive
TUBs [6 submucosal and 9 advanced cancers that
invaded the muscularis propria or deeper tissues (the
tubular component of each tumour was assessed to be
more than 30%)]. Each stomach was fixed in formalin and
embedded in paraffin wax. These were selected at ran-
dom from the materials diagnosed in our department
from 1996 to 2008. Histological types and tumour stages
were determined according to the Japanese Classification
of Gastric Cancer [19] and p TNM staging, respectively.
When a mucosal histological pattern was found to be het-
erogeneous in an individual invasive tumour, the part
with the lowest grade of atypism was taken as the
mucosal sample that can prevent the possibility of re-
invasion of invasive cancer cells into the mucosa. In inva-
sive cancers, DNA samples were obtained from intramu-
cosal and invasive parts.
Immunohistochemistry
Immunohistochemical staining was performed with
monoclonal antibodies to p53 protein (DO-7, 1:100;
Dako, Glostrup, Denmark). After antigen retrieval of tis-
sue sections in distilled water at 121°C for 5 min, immu-
n o r e a c t i v i t y  w a s  d e t e c t e d  b y  a n  i n d i r e c t  b i o t i n -
streptavidin-peroxidase method using the Histofine Kit
(Nichirei, Tokyo, Japan) and diaminobenzidine reaction.
The sections were counterstained with haematoxylin.
Slides of the negative control without the primary anti-
body and those of the positive control were processed in
parallel.
Laser microdissection and DNA preparation
Tumour cells were obtained from 5-μm-thick tissue sec-
tions using a LMD6000 laser microdissection system
(Leica Microsystems, Wetzlar, Germany). For individual
tumours, cancer cells were obtained from areas >3 mm2,
where cancer cells accounted for ≥90% of the total cell
count. These cancer cells were digested in 200 μl of pro-
teinase K solution at a concentration of 200 μg/ml for
approximately 70 h at 37°C, followed by phenol/chloro-
form DNA extraction.
Whole genome amplification
Sample DNA was amplified using degenerate oligonucle-
otide-primed polymerase chain reaction (DOP-PCR) in 2
phases, as described previously [20], which resulted in
PCR products more than 2 kb in size, suitable for nick-
translation labelling for CGH.
For array CGH, sample DNA was amplified using the
GenomePlex Tissue Whole Genome Amplification Kit
(WGA2 Kit; Sigma, St. Louis, USA) [21]. For some DNA
samples that could not be sufficiently amplified, the
WGA5 Kit (Sigma) was employed.
CGH (hybridization, probe DNA labelling and digital image 
analysis)
DOP-PCR-amplified tumour and normal DNA was
labelled using fluorescein-12-dUTP and tetramethylrho-
damine-5-dUTP (Roche, Mannheim, Germany), respec-Nakayama et al. BMC Cancer 2010, 10:311
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Table 1: Summary of clinical, histopathological and molecular genetic data of 25 tubular adenocarcinoma of stomach
Case No. Age/sex Histological type* Invasion** LN** Stage ** CGH p53 IHC TP53 mutation
M1 57/M tub1 T1(M) N0 IA c/a + NT
M2 72/M tub1 T1(M) N0 IA c/a + NT
M3 67/F tub1 T1(M) N0 IA c/a - -
M4 67/M tub1 T1(M) N0 IA c/a - -
M5 74/M tub1 T1(M) N0 IA c/a + -
M6 65/M tub1 T1(M) N0 IA c/a + -
M7 67/F tub1 T1(M) N0 IA c/a + -
M8 70/F tub1 > pap T1(M) N0 IA c/a - -
M9 51/M tub1 > tub2 T1(M) N0 IA c/a + -
M10 52/M tub2 T1(M) N0 IA c/a + -
M11 57/F tub2 T1(M) N0 IA NT/a - -
M12 89/M tub2 T1(M) N0 IA NT/a + +
M13 70/M tub1 T1(M) N0 IA NT/a - NA
S1m 73/F tub2 T1(SM) N0 IA c/a + -
S1i NT/a + -
S2m 81/F pap T1(SM) N1 IB c/a + -
S2i NT/a + +
S3m 79/M tub1 T1(SM) N0 IA c/a + +
S3i NT/a + +
S4m 63/M tub2 > tub1 T1(SM) N0 IA c/NT + NT
S5m 75/M pap > tub2 T1(SM) N1 IB c/NT + NT
S6m 79/M pap T1(SM) N1 IB c/NT + NT
A1m 71/M tub2 T2(SS) N2 IIIA c/a null -
A1i NT/a null NA
A2m 73/M tub1 > tub2 T2(SS) N0 IB c/a + -
A2i NT/a + +
A3m 56/M pap T2(SS) N1 II c/a + -
A3i NT/a + +
A4m 81/M tub2/pap T2(SS) N2 IIIA c/a null -
A4i NT/a null +
A5m 56/M tub1 T2(MP) N0 IB c/NT - NT
A5i NT/NA - NA
A6m 45/F tub2 T2(SS) N1 IB c/NT + NT
A7m 79/F tub2 T2(MP) N1 IB c/NT +/- NT
A8m 69/M tub1 T3(SE) N2 IIIB c/a null -
A8i NT/a null NA
A9m 67/F tub2 T2(SS) N1 II c/a + -
A9i NT/a + +
* Japanese classification of gastric carcinoma; ** pTNM classification. In the column of Case No, M = intramucosal cancer; S = cancer involving the 
submucosa; A = advanced cancer; m = mucosal part; i = invasive part. In the column of CGH, c = chromosomal CGH; a = array CGH. In the column 
of p53 immunohistochemistry (IHC); "+" indicates diffusely (>70%) positive nuclei, "-" indicates sporadically (<5%) positive nuclei; "null" indicates 
no immunoreactivity at all. In the column of TP53 mutation; "+" and "-" indicate presence and absence of mutation, respectively; NA = not 
assessable; NT = not tested.Nakayama et al. BMC Cancer 2010, 10:311
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tively, by nick translation [15]. Hybridization and image
analyses were performed as described previously [22].
Gains and losses in DNA copy numbers were defined by
green to red ratios >1.2 and <0.8, respectively. Chromo-
somes 1p32-pter, 16p, 19, 22 and Y were excluded from
these analyses.
Array CGH
Oligo CGH microarray (60 K, 60-mer) (Agilent, Santa
Clara, USA) was used in this study, according to the man-
ufacturer's instructions. In brief, tumour and control
DNA was non-enzymatically labelled with Cy5 and Cy3,
respectively, using the Genome DNA ULS Labelling Kit
(Agilent) and competitively hybridized to the microarray.
Using Feature Extraction Ver.9.5.3 (Agilent), the fluores-
cence intensity of the tumours and controls was calcu-
lated from the hybridized array images captured using a
DNA microarray scanner (Agilent). Copy-number gains
and losses were defined as base 2 logarithm of the tumour
signal intensity to the reference signal intensity ratio
more than 0.3219 and less than -0.3219, respectively.
Mutation analysis for TP53
PCR primer sets were prepared for exons 5-8 of TP53,
which hybridize to the flanking introns of each exon. See
additional file 1 for primer sequences. The first PCR mix-
ture consisted of a buffer, 200 μM dNTPs, 1.5 mM MgCl2,
0.8 μM primer, 1 ng/μl sample DNA and 0.5 U Platinum
Taq (Invitrogen, California, USA) in a 25-μl final volume.
After initial denaturation at 94°C for 2 min, 40 cycles of
PCR were performed at 94°C for 30 sec, 54°C for 1 min
and 72°C for 1 min, followed by the final extension step at
72°C for 10 min. After confirmation of PCR products by
agarose gel electrophoresis, sequence PCR was per-
formed using the BigDye Terminators v1.1 Cycle
Sequencing Kit (Applied Biosystems, California, USA).
The reaction mixture consisted of a buffer, 2 μl of the first
PCR product, 0.15 μM primer and 0.5 μl BigDye Termi-
nator V 1.1 in a 10-μl final volume. After initial denatur-
ation at 96°C for 1 min, 25 cycles of PCR were performed
at 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min. The
forward and reverse sequences were determined using
the ABI PRISM 3100 Genetic Analyser (Applied Biosys-
tems). Mutations were detected by comparing these sam-
ples to the reference DNA sequence (GenBank accession
number: HSU94788). Allelic status was determined using
the ratio of mutant to wild-type peak levels in sequencing
profiles.
Statistical analyses
Contingency tables were analysed by Fisher's exact test
and Cochran-Armitage tests. Differences of 2-sided tests
with P < 0.05 were considered to be statistically signifi-
cant.
Results
Immunohistochemistry for p53
Staining patterns were considered overexpressed only
when ≥70% tumour cells showed positively stained nuclei
when viewed in a low-power field. Eight of the 13 intra-
mucosal cancers, all the 6 submucosal cancers and 4 of
the 9 advanced cancers showed diffusely positive nuclear
staining for p53 (Table 1). A focal staining pattern was
observed in case #A7. A pattern was considered negative
(representing the wild-type TP53) when the presence of
sparse, sporadic and weak nuclear staining was observed
in <5% of the nuclei. A null staining pattern was observed
in cases #A1, #A4 and #A8, suggesting a non-sense muta-
tion of TP53 [23].
Chromosomal CGH
Twenty-five samples from 25 cases (10 mucosal, 6 sub-
mucosal and 9 advanced cancers) were used for chromo-
somal CGH. All these samples were obtained from
intramucosal lesions that showed the lowest grade of
atypism.
While 4q+ occurred in the majority (6/9 cases) of
advanced TUBs, it was not detected in the 16 early TUBs
(P = 0.0005). Another significantly different chromo-
somal change between early and advanced cancers was
11q+, which was detected in 11 of the 16 early cancers
and 2 of the 9 advanced cancers (P = 0.0414). Of the 10
intramucosal TUBs examined, 3 showed loss of 8q (8q-)
and/or gain of 17p (17p+), while 7 and 2 showed 8q+ and
17p-, respectively. Of the 15 mucosal samples of invasive
TUBs examined, 3 and 4 showed 8q- and 17p+, respec-
tively, while 7 and 6 showed 8q+ and 17p-, respectively.
Array CGH
Thirty-one samples from 22 cases (13 mucosal, 3 submu-
cosal and 6 advanced cancers) were assessed using array
CGH (Figure 1). DNA samples were obtained from intra-
mucosal and/or invasive lesions.
As shown in Figure 1 and Table 2, concomitant loss of
MYC (MYC-) and gain of TP53 (TP53+) were detected in
9 of the 13 intramucosal TUBs, 7 of the 9 mucosal sam-
ples of invasive TUBs, 1 of the 3 invasive samples of sub-
mucosal cancers and none of the 6 invasive samples of
advanced cancers. A pattern of MYC+ and/or TP53- was
detected in 3 of the 13 intramucosal cancers, none of the
9 mucosal samples of invasive TUBs, 1 of the 3 invasive
samples of 3 submucosal cancers and 5 of the 6 invasive
samples of 6 advanced cancers.
Based on the overall array CGH patterns, genetic lin-
eages were found to be discontinuous and continuous
between the mucosal and invasive parts in 5 advanced
and 3 submucosal cancers, respectively. As shown in Fig-
ure 2, the sample from the mucosal part of #S3 showed
4p-, 4q-, 8q+, 9p-, 13q+, 15q-, 18q-, 20q+ and Y- , whileNakayama et al. BMC Cancer 2010, 10:311
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the sample from the invasive part of #S3 inherited the
same aberrations from the mucosal part, showed addi-
tional aberrations (2q-, 7p+, 8p-, 10p+, 14q+ and 20q+)
and lost 4p- and 22q+. In #S1, gains of 1q, 14q, 19 and 20,
and loss of 18q was common in mucosal and submucosal
samples, though the gains of 1q, 14q, 19q and 20 in the
submucosa were slightly less than the significant level. In
#S2, a common change in both the mucosal and submu-
cosal parts was a gain of 20p. The submucosal sample
showed additional gains in 10p, 12 and 13q and losses in
3q, 4, 5, 8p, 9p, 9q, 10q, 12p, 14q, 16 and 19p. The
mucosal sample showed loss of 18q, which was restored
in the submucosal sample, possibly by uniparental dis-
omy [24,25]. In #A1, #A3, #A4, #A8 and #A9, aberrations
in the samples from the mucosal parts were not detected
in those of the invasive parts. In #A2, the continuity of
genetic lineages could not be assessed because of the
absence of significant copy-number alterations in the
mucosal part.
TP53 mutation analysis
Mutations were detected in 7 of the tumours that were
examined for sequence analysis of exons 5-8 of TP53 (Fig-
ure 1, Table 3): 1 of the 10 intramucosal cancers, 2 of the 3
submucosal cancers and all 4 advanced cancers (only the
invasive parts). In all these 7 tumours, the TP53 allele was
hemizygous except in 1 intramucosal cancer (#M12) with
a heterozygous pattern for an exon-8 mutation (Figure 3)
and a diffuse or a null pattern for p53, as indicated by
immunohistochemistry. No TP53 mutation was detected
in p53- samples, as shown in Figure 4. In p53+/null sam-
Figure 1 Array CGH data of MYC and TP53 and TP53 sequencing data in early and advanced tubular adenocarcinomas of stomach. Early can-
cers are divided into intramucosal (m) cancers and submucosal (sm) cancers. Refer to Table 1 for sample numbers. Numerals are mean test/reference 
ratios of array CGH. Significant losses and gains are indicated with red and green, respectively. Wild type (wt) and mutation in exon (ex) and intervening 
sequence (IVS) of TP53 are indicated with yellow and gray, respectively.
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Table 2: Alterations of MYC and TP53 copy numbers in early and advanced tubular adenocarcinomas of stomach
Tumour depth Mucosa Submucosa MP or deeper -
Mucosal part SM Mucosal part Deep
cCGH
(10)
aCGH
(13)
cCGH
(6)
aCGH
(3)
aCGH
(3)
cCGH
(9)
aCGH
(6)
aCGH
(6)
8q(MYC)+ 7 2 (2*) 3 01  ( 1 * ) 4 03  ( 2 * )
8q(MYC)- 3 9 (9**) 3 2 (2**) 1 (1**)05 (5**) 1 (0**)
17p(TP53)+ 3 10(9**) 3 2 (2**) 2 (1**) 1 6 (5**) 1 (0**)
17p(TP53)- 2 3 (2*) 2 01  ( 1 * ) 4 04  ( 2 * )
SM, the submucosa; MP, the muscularis propria. cCGH and aCGH, chromosome- and array-based comparative genomic hybridisation; Numerals 
in parentheses indicate the total number of the samples examined. Bold letters indicates the results of aCGH. Asterisks in parentheses indicate 
concomitance of MYC+ and TP53-. Double asterisks indicate concomitance of MYC- and TP53+.Nakayama et al. BMC Cancer 2010, 10:311
http://www.biomedcentral.com/1471-2407/10/311
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ples, 2 of the 15 samples of the mucosal part showed
TP53 mutation, whereas 6 of the 7 samples of invasive
part showed TP53 mutation (P = 0.0023). In 1 of the sub-
mucosal cancers showing TP53+ and a hemizygous
mutation (the invasive part of #S2), TP53+ may reflect
uniparental polysomy [24,25].
On the other hand, in the mucosal samples, the diffuse/
null pattern was often associated with wild-type TP53. In
order to explain this finding, the MDM2 copy number
was examined using array CGH data. Of a total of 22
samples assessed for TP53 mutation analysis, MDM2
showed copy-number loss in 10 of the 14 samples with
wild-type TP53 and 1 of the 8 samples with TP53 muta-
tion (P = 0.0237).
Discussion
In intramucosal TUBs, chromosomal CGH revealed 8q-
and/or 17p+ at a frequency of 3 out of 10 tumours exam-
ined; these changes were more common in a previous
study that used random priming labelling [18]. In the
present study, 8q+ was frequently detected both in intra-
mucosal cancers (7/10) and in invasive cancers (7/15);
however, the above-mentioned previous data rarely
showed 8q+. These discrepancies may reflect differences
in the labelling methods used; CGH results with nick
translation labelling or random priming labelling were
compared to FISH signals, and it was found that nick
translation labelling not infrequently showed false-posi-
tive gains [26]. However, using the same labelling condi-
Figure 2 Array CGH profiles. The chromosomal regions of copy number aberrations in the mucosal part of #S3 (S3m) are included basically in those 
in the invasive part (S3i), whereas those in the mucosal part of #A1 (A1m) are different from those of the invasive part (A1i).
S3m
S3i
A1i
A1m
A4m
A4i
A9m
A9i
MYC TP53Nakayama et al. BMC Cancer 2010, 10:311
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tions, significant differences in the incidence of 4q+ and
11q+ were detected between early and advanced cancers,
possibly reflecting differences in genetic lineages between
them. Chromosomal CGH data of advanced cancers in
this study were consistent with previous chromosomal
CGH data obtained with nick translation labelling for
advanced GCs (i.e. 17p- and 8q+ were quite common)
[27-30].
Although clinically discernible early cancers are gener-
ally considered the precursors of advanced cancers [5,6],
the intramucosal and invasive parts of advanced TUBs
often showed discordant copy numbers of MYC  and
TP53 in this study: MYC- and TP53+ in 5 of the 6 sam-
Table 3: Copy number changes of TP53 and MYC and p53 immunoreactivity in the samples tested for mutation analyses
Case No. MYC TP53 Mutation of TP53 exons 5-8 Mutant allele MDM2 p53 IHC
M3 - + wt - -
M4 - + wt ns -
M5 - + wt ns +
M6 - + wt - +
M7 ns + wt - +
M8 - + wt ns -
M9 - + wt ns +
M10 - + wt - +
M11 ns - wt ns -
M12 + - Exons 5/8 hemi/hetero ns +
M13 + - NA ns -
S1m - + wt - +
S1i - + wt - +
S2m - + wt - +
S2i ns + exon 7 hemi ns +
S3m ns ns exon 8 hemi ns +
S3i + - exons 5/6/8 hemi ns +
A1m - + wt - null
A1i + - NA - null
A2m - + wt ns +
A2i + - exon 8 hemi ns +
A3m - + wt ns +
A3i - - exon 5 hemi - +
A4m - + wt - null
A4i ns ns exon 5 hemi ns null
A8m ns + wt - null
A8i + - NA ns null
A9m - + wt - +
A9i + + exon 6 hemi ns +
ns = not significant; wt = wild type; NA = not assessable; hemi = hemizygous; hetero = heterozygous.
M12, exon 5: R175H (CGC > CAC), C182C (TGC > TGT), S183L (TCA > TTA); exon 8: R267R (CGG > CGA)
S2i, exon 7: C242F (TGC > TTC)
S3m, exon 8: R273S (CGT > AGT)
S3i, exon 5: A161V (GCC > GTC); exon 6: T211I (ACT > ATT); exon 8: R273S (CGT > AGT)
A2i, exon 8: R273 H (CGT > CAT)
A3i, exon 5: A161T (GCC > ACC)
A4i, exon 5: IVS5+1G > T
A9i, exon 6: Y220C (TAT > TGT)Nakayama et al. BMC Cancer 2010, 10:311
http://www.biomedcentral.com/1471-2407/10/311
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ples of the mucosal parts, as commonly as in the intramu-
cosal cancers examined, and MYC+ and/or TP53- in 5 of
the 6 samples of the invasive parts. In addition, based on
the overall array CGH pattern of the mucosal and inva-
sive parts of tumours, a discontinuous genetic lineage was
found in 5 of the 6 advanced cancers. Therefore, it
appears that the tumour clones in the mucosal parts of
the advanced cancers were not precursors of the invasive
part, but minute intramucosal cancers that probably
coexisted with the invasive cancers. It has been reported
that multiple minute cancers are more common in TUBs
than in undifferentiated-type GCs [31]. In advanced
TUBs, the intramucosal precursor of an invasive compo-
n e n t  m i g h t  h a v e  b e e n  l o s t  d u e  t o  u l c e r a t i o n  i n  t h e
tumour, or the precursor was not examined because it did
not coincide with the part of the lowest grade of atypism,
to which the examination of the mucosal part of invasive
GCs was confined in the present study.
On the other hand, in submucosal cancers, a continu-
ous genetic lineage was found in all the 3 submucosal
tumours examined. It may be because the mucosal part is
basically retained in early GCs and because the mucosal
precursor of an invasive component showed the lowest
grade of atypism and was not excluded from the present
array analyses. The mucosal and invasive parts had com-
mon regions of copy number aberrations with concor-
dant breakpoints, and most of the changes in the mucosal
part were included in those of the invasive part. At the
gene level, the copy numbers of MYC  and  TP53  were
consistent between the mucosal and submucosal parts in
2 of the 3 submucosal cancers.
The TP53- and/or MYC+ pattern was detected not only
in the invasive parts of 1 of the submucosal cancers and
most of the advanced cancers but also in 3 of the 13 intra-
mucosal cancers. In these tumours, p53 immunohis-
tochemistry showed a diffuse or null (mutation) pattern
(Tables 1 and 3), suggesting that the TP53- may reflect
LOH and the resultant inactivation of wild-type TP53.
Sequencing analyses of the mutation hot spots of TP53
have demonstrated that hemizygous mutations (i.e.
mutation and LOH) were detected in the mucosal sam-
ples of 1 of the 3 intramucosal cancers and 1 submucosal
cancer with a TP53- pattern, as well as the invasive parts
of the 4 advanced cancers that were informative for TP53
mutation analysis. Such inactivation of wild-type TP53,
which may cause further genomic instability, has been
frequently reported in advanced GCs [15,17]. The MYC
gene locus is also known to frequently show copy-num-
Figure 3 TP53 mutation patterns. A heterozygous mutation with a significant wild-type component in exon 8 (A) and a hemizygous mutation in 
exon 5 (B) in an intramucosal cancer (#M12). Mutations in the other tumours examined were hemizygous as shown in C (#S2).
Figure 4 Relationships among p53 immunohistochemistry, copy 
number of TP53 and hot spot mutation of TP53. For "p53+" and 
"p53-", see the legend in Table 1. "TP53 +", "TP53 -" and "TP53 n/s" indi-
cate significant copy-number gain and loss, and no significant change, 
respectively. Numerals in parentheses indicate the number of samples 
in invasive parts. Numerals are sample numbers. Numerals in paren-
theses indicate the number of samples in invasive parts. NA = not as-
sessable.
wild type:
13
Mutant: 2
wild type:
4
Mutant:
6
NA: 2
wild type: 1
NA: 1
TP53+: 3
TP53: 2
TP53+:
16 (3)
TP53ns: 
2 TP53:
6 (5)
Invasive part
Mucosal part
p53+/null p53   Nakayama et al. BMC Cancer 2010, 10:311
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ber gains or amplifications in various advanced cancers
[32]. MYC+/TP53- may thus be justified as the signature
of aggressive GC.
It has been reported that LOH as well as mutations of
TP53 are more frequently detected in advanced GCs than
in early GCs [17,33], and that, within early GCs, TP53
mutations are more frequently detected in submucosal
TUBs than in intramucosal TUBs [34,35]. This tendency
was also observed in the present study, but mutation
analyses indicated that hot spot mutations were not
detected in the mucosal part of the tumours, except in 1
intramucosal cancer (#M12). In addition, copy-number
loss of MDM2, which plays a role in p53 degradation [36],
correlated with diffuse p53 overexpression in the absence
of a TP53  mutation. This phenomenon is scarcely
reported, but could be one of the mechanisms of p53
overexpression in early GCs.
In early cancers, there may be dormant and invasive
components as well as true precursors of advanced can-
cers. Among the early cancers examined in the present
study, an invasive part of 1 tumour (#S3) and 3 intramu-
cosal cancers (#M11, #M12 and #M13) showed the signa-
ture of aggressive cancer (MYC+ and/or TP53-) and
frequent mutations of TP53; however, in 1 submucosal
cancer (#S1), the invasive parts showed the signature of
dormant cancer (MYC-/TP53+). Submucosal cancers
with the signature of dormant cancer may be in the sub-
mucosa for a long time, and therefore, they provide a
greater opportunity for clinical detection as submucosal
cancers. However, in order to eradicate advanced cancers,
early cancers with the signature of aggressive cancer must
be detected, such as tumours #S3 and #M11-#M13. If this
hypothesis of dormant and aggressive signatures is con-
firmed by studies with a larger number of cases, the dif-
ferentiation between the 2 signatures can be applied to
gastric biopsy specimens.
Conclusions
These array CGH-based analyses have demonstrated that
the copy numbers of MYC and TP53 have high discrimi-
native power for differentiation between genetic lineages
in individual gastric TUBs. This study has shown that
genetic lineages are often different between early and
advanced TUBs and that MYC-/TP53+ and MYC+ and/
or TP53- may be signatures of dormant and aggressive
TUBs, respectively, in the stomach.
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